On January 24, 2018 Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases, reported that the Company will present at the 14th Annual Noble Capital Markets Investor Conference being held January 29 & 30, 2018 in Boca Raton, FL (Press release, Cyclacel, JAN 24, 2018, View Source [SID1234523544]). Spiro Rombotis, President & Chief Executive Officer will provide an overview of the Company and progress in key programs.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Information on the presentation is as follows:
Event: 14th Annual Noble Capital Markets Investor Conference
Date: Tuesday, January 30, 2018
Time: 3:00 pm ET
Location: W Hotel, Studio 3, Fort Lauderdale, FL
A live webcast of the presentation will be available through the Company’s website: www.cyclacel.com. The webcast will be archived for 90 days.